JAMA Oncology· 2020Q1

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

David A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland et al.

1,474citations
Q1SCImago
2020year

Short summary

A phase 3 trial (n=369) found nivolumab did not improve overall survival (OS) compared to bevacizumab in recurrent glioblastoma, with median OS of 9.8 vs. 10.0 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine